Use of a personalized phenytoin dosing approach to manage difficult to control seizures in an infant with a SCN2A mutation

Eur J Clin Pharmacol. 2019 May;75(5):737-739. doi: 10.1007/s00228-019-02629-w. Epub 2019 Jan 15.

Tatjana Welzel^{1

2}, Victoria C Ziesenitz^{3

4}, Salome Waldvogel⁴, Sabrina Scheidegger⁴, Peter Weber⁵, Johannes N van den Anker^{3

6}, Verena Gotta³

¹ Pediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel UKBB, University of Basel, Spitalstrasse 33, CH 4056, Basel, Switzerland. tatjana.welzel@ukbb.ch.
² Pediatric Rheumatology, University Children's Hospital Basel UKBB, University of Basel, Spitalstrasse 33, CH 4056, Basel, Switzerland. tatjana.welzel@ukbb.ch.
³ Pediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel UKBB, University of Basel, Spitalstrasse 33, CH 4056, Basel, Switzerland.
⁴ Department of Neonatology, University Children's Hospital Basel UKBB, University of Basel, Spitalstrasse 33, CH 4056, Basel, Switzerland.
⁵ Neuropediatrics and Developmental Medicine, University Children's Hospital Basel UKBB, University of Basel, Spitalstrasse 33, CH 4056, Basel, Switzerland.
⁶ Division of Clinical Pharmacology, Children's National Health System, 111 Michigan Avenue NW, Washington, DC 20010, USA.

No abstract available

Publication types